Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02568566 · ClinicalTrials.gov registry record · Phase 2
Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants
A Phase 2 study of Human Papillomavirus-Related Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 201
- Enrollment target
- 2
- Study locations
NCT02568566 is a Phase 2 study of Human Papillomavirus-Related Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 201 participants, below the 378-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02568566, a Phase 2 study of Human Papillomavirus-Related Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 201 participants
- Enrollment target
- 2
- Study locations
Study Summary
Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well does the nonavalent HPV vaccine (which can prevent nine different types of HPV) work when given in an alternative dosing schedule to heathy young research participants.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Recombinant Human Papillomavirus Nonavalent Vaccine
Study Locations (2)
Arizona
- Banner University Medical Center - Tucson - Tucson
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2016-05-19 |
| Est. Completion | 2027-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02568566
The ClinicalTrials.gov registry entry for NCT02568566 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 378-participant average among 7 other Human Papillomavirus-Related Carcinoma trials with a reported enrollment target (47% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Human Papillomavirus-Related Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02568566 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.
Frequently Asked Questions
What is clinical trial NCT02568566 about?
NCT02568566 is a clinical study titled "Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants". Human papillomavirus (HPV) is a common sexually-transmitted virus which causes infections that usually last only a few months, but sometimes can last a long time and cause cancers of the cervix, vagina, vulva, anus or oropharynx over many years among adults. This phase IIA trial studies how well doe...
What is the current status of trial NCT02568566?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2016-05-19. Estimated completion is 2027-01-10.
What conditions does trial NCT02568566 study?
This clinical trial studies the following conditions: Human Papillomavirus-Related Carcinoma.
What interventions are being tested in trial NCT02568566?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Recombinant Human Papillomavirus Nonavalent Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02568566?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02568566 being conducted?
This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Papillomavirus-Related Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
RECRUITING · Phase 1
-
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
RECRUITING · NA
-
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
ACTIVE NOT RECRUITING · Phase 1
-
MeFirst: A Tailored Intervention to HPV Vaccine Decision Making
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.